Abstract
Chromogenic in situ hybridization (CISH) has shown the potential to replace fluorescence in situ hybridization (FISH) to determine HER2 gene status. To validate the reliability of CISH, we used 226 consecutive breast carcinomas from 2 institutions and tested CISH and FISH on the same tumor set simultaneously at different test sites. Besides manufacturers' scoring criteria, the new American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines were used to interpretHER2 status. The concordance between CISH and FISHfor positive and negative results was 98.5% at site A and 98.6% at site B using the manufacturers' criteria, and 99.0% at site A and 99.1% at site B using the ASCO/CAP criteria. Reproducibility of CISH results was more than 98.0% among 3 sites using the manufacturers' criteria and 100.0% between 2 sites using the ASCO/CAP criteria. Our results confirm that CISH is reliable for HER2 testing per ASCO/CAP guidelines.
Original language | English (US) |
---|---|
Pages (from-to) | 490-497 |
Number of pages | 8 |
Journal | American journal of clinical pathology |
Volume | 131 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2009 |
Keywords
- American Society of Clinical Oncology
- CISH
- Chromogenic in situ hybridization
- College of American Pathologists
- Concordance
- FISH
- Fluorescence in situ hybridization
- HER2
- Immunohistochemistry
- Reproducibility
ASJC Scopus subject areas
- Pathology and Forensic Medicine